SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000926617-24-000031
Filing Date
2024-04-26
Accepted
2024-04-26 16:56:36
Documents
13
Period of Report
2024-04-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K awh-20240422x8k.htm   iXBRL 8-K 65733
  Complete submission text file 0000926617-24-000031.txt   188322

Data Files

Seq Description Document Type Size
2 EX-101.SCH awh-20240422.xsd EX-101.SCH 2550
3 EX-101.LAB awh-20240422_lab.xml EX-101.LAB 15612
4 EX-101.PRE awh-20240422_pre.xml EX-101.PRE 11194
16 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240422x8k_htm.xml XML 5016
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 24884843
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)